Celgene Allows Earlier Cancer Drug Generic In Patent Deal
Celgene Corp. has agreed to allow an India-based drugmaker to sell a generic version of its blood cancer treatment in the U.S. more than a year before the last-to-expire patent covering...To view the full article, register now.
Already a subscriber? Click here to view full article